Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug229 | Ad5FGF-4 Wiki | 0.35 |
| drug166 | AVP 4 Wiki | 0.35 |
| drug167 | AVP I Wiki | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4768 | Xpert Pro stent Wiki | 0.35 |
| drug3074 | Pacel BPC Wiki | 0.35 |
| drug3133 | Percutaneous Transluminal Angioplasty (PTA) Device Wiki | 0.35 |
| drug3851 | Saline placebo Wiki | 0.35 |
| drug2679 | Motivational social support from nurse with additional support from significant other Wiki | 0.35 |
| drug3075 | Pacel FDPC Wiki | 0.35 |
| drug2082 | Immunfluorescence Wiki | 0.35 |
| drug788 | COVID 19 impact Wiki | 0.35 |
| drug424 | Attention control Wiki | 0.35 |
| drug311 | Angiography Wiki | 0.35 |
| drug2678 | Motivational social support from nurse Wiki | 0.35 |
| drug3466 | QFR Wiki | 0.35 |
| drug4319 | Telemedicine visit Wiki | 0.35 |
| drug2538 | Mechanical Trombectomy Wiki | 0.35 |
| drug2081 | Immune response study Wiki | 0.35 |
| drug1431 | ESPRIT™ BTK Device Wiki | 0.35 |
| drug197 | Absolute Pro LL stent Wiki | 0.35 |
| drug4343 | Temsirolimus Wiki | 0.35 |
| drug3376 | PressureWire X Wiki | 0.35 |
| drug4184 | Supera 7.5 OD stent Wiki | 0.35 |
| drug2488 | MULTI-LINK 8 SV stent Wiki | 0.35 |
| drug2487 | MULTI-LINK 8 LL stent Wiki | 0.35 |
| drug4764 | XIENCE PRIME BTK stent Wiki | 0.35 |
| drug2489 | MULTI-LINK 8 stent Wiki | 0.35 |
| drug168 | AVP II Wiki | 0.35 |
| drug2099 | In-person postoperative visit Wiki | 0.35 |
| drug554 | Baricitinib Wiki | 0.12 |
| drug3195 | Placebo Wiki | 0.01 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003324 | Coronary Artery Disease NIH | 0.47 |
| D023921 | Coronary Stenosis NIH | 0.35 |
| D023903 | Coronary Restenosis NIH | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D060050 | Angina, Stable NIH | 0.35 |
| D009203 | Myocardial Ischemia NIH | 0.30 |
| D000787 | Angina Pectoris NIH | 0.25 |
| D006331 | Heart Diseases NIH | 0.18 |
| D058729 | Peripheral Arterial Disease NIH | 0.18 |
| D003327 | Coronary Disease NIH | 0.13 |
| D007238 | Infarction NIH | 0.10 |
| D020521 | Stroke NIH | 0.09 |
| D004617 | Embolism NIH | 0.08 |
| D004630 | Emergencies NIH | 0.06 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001677 | Coronary artery atherosclerosis HPO | 0.47 |
| HP:0005145 | Coronary artery stenosis HPO | 0.35 |
| HP:0001658 | Myocardial infarction HPO | 0.30 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001681 | Angina pectoris HPO | 0.25 |
| HP:0004950 | Peripheral arterial stenosis HPO | 0.13 |
| HP:0001297 | Stroke HPO | 0.09 |
Navigate: Correlations HPO
There are 8 clinical trials
The purpose of this study is to determine whether a single intracoronary infusion of an adenovirus serotype 5 virus expressing the gene for human fibroblast growth factor-4 (Ad5FGF-4) is effective in improving angina-limited exercise duration, angina functional class, frequency of angina attacks, frequency of nitroglycerin usage, and quality of life. Half of the study participants will receive Ad5FGF-4, and half will receive placebo. The primary endpoint is the change from baseline to Month 6 in Exercise Tolerance Test (ETT) duration. Long-term safety of Ad5FGF-4 will also be assessed.
Description: Modified Bruce Protocol with exercise duration limited by angina or angina equivalent
Measure: Change in Exercise Tolerance Test (ETT) duration Time: Baseline and Month 6Description: Canadian Cardiovascular Society (CCS) angina classification
Measure: Change in patient functional status (CCS class) Time: Baseline and Month 6Description: Average weekly angina episodes
Measure: Change in weekly angina frequency Time: Baseline and Month 6Description: Average weekly nitroglycerin usage
Measure: Change in weekly nitroglycerin usage Time: Baseline and Month 6Description: Seattle Angina Questionnaire
Measure: Change in quality of life Time: Baseline and Month 6Description: Adverse events and clinical laboratory testing
Measure: Safety of Ad5FGF-4 Time: Through Month 6Description: Occurrence of clinically significant events
Measure: Long-term safety of Ad5FGF-4 Time: Through Month 60The overall purpose of the FAVOR III China trial is to investigate if a strategy of quantitative flow ratio (QFR)-guided percutaneous coronary intervention (PCI) yields superior clinical outcome and cost-effectiveness compared to a strategy of standard coronary angiography-guided PCI in evaluation of patients with coronary artery disease.
Description: A composite of all-cause mortality, any myocardial infarction and any ischemia-driven revascularization
Measure: MACE Time: 1 yearDescription: all-cause mortality, any spontaneous myocardial infarction and any ischemia-driven revascularization
Measure: MACE excluding peri-procedural MI (Major secondary endpoint) Time: 1 yearDescription: Cardiovascular, non-cardiovascular and undetermined death
Measure: Death Time: 1 month, 6 months, 1 year, 2 years and 3 yearsDescription: Target vessel related and non-target vessel related MI
Measure: MI Time: 1 month, 6 months, 1 year, 2 years and 3 yearsDescription: The ischemia driven and non-ischemia driven TVR
Measure: Target vessel revascularization (TVR) Time: 1 month, 6 months, 1 year, 2 years and 3 yearsDescription: The The ischemia driven and non-ischemia driven Revascularization
Measure: Any coronary artery revascularization Time: 1 month, 6 months, 1 year, 2 years and 3 yearsDescription: Definite and probable stent thrombosis during acute, sub-acute, late, and very late phase according to the Academic Research Consortium (ARC)-2
Measure: Definite or probable stent thrombosis Time: 1 month, 6 months, 1 year, 2 years and 3 yearsDescription: PCI strategy changes following QFR and three-dimension quantitative coronary angiography (3D-QCA)
Measure: The PCI strategy changes based on the QFR and 3D-QCA Time: During the procedureDescription: Costs include direct clinical costs during the initial hospitalization and other resources used, main cardiovascular medication expenses, and outpatient and/or hospitalization expenses associated with MACE.
Measure: Cost during 1-year follow-up Time: 1 month, 6 months, 1 yearDescription: QALYs determined using EuroQol five dimensions questionnaire (EQ-5D) in official Chinese version, to assess the quality of life.
Measure: Quality-adjusted-life-years (QALYs) index Time: 1 month, 6 months, 1 yearAfter a 30-year decline, heart disease is projected to increase up to 18% by 2030. Participation rates in cardiac rehabilitation remain extremely low and hopeless individuals are less likely to participate. This innovative study has the potential to advance science, improve patient care, and improve patient outcomes by demonstrating the effectiveness of the Heart Up! program to increase physical activity and reduce hopelessness in patients with heart disease. Hopelessness is associated with a 3.4 times increased risk of mortality or nonfatal myocardial infarction in patients with ischemic heart disease (IHD), independent of depression. Hopelessness has been identified in 27-52% of patients with IHD and can persist for up to 12 months after hospital discharge. Hopelessness, a negative outlook and sense of helplessness toward the future, can be a temporary response to an event (state) or a habitual outlook (trait). Hopelessness is associated with decreased physical functioning and lower physical activity (PA) levels in individuals with IHD. While research has investigated strategies to increase PA among IHD patients in general, the study team is the only group to design an intervention to promote PA specifically in hopeless IHD patients. The purpose of this randomized controlled trial is to establish the effectiveness of our 6-week mHealth intervention (Heart Up!) to promote increased PA in hopeless patients with IHD. A total of 225 hopeless IHD patients will be enrolled from a large community teaching hospital in the Midwest. Patients will be randomized (75 per group) to one of three groups: 1) motivational social support (MSS) from a nurse, 2) MSS from a nurse with additional significant other support (SOS), or 3) attention control (AC). It is hypothesized that 1) The MSS with SOS group will have the greatest increase in average minutes of moderate to vigorous PA per day at 8 and 24 weeks as compared to the MSS only or AC groups; 2) Greater increase in minutes of moderate to vigorous PA per day will be associated with decreased state hopelessness levels from baseline to weeks 8 and 24; and 3) Increased social support and increased motivation will mediate the effects of Heart Up! on a greater increase in moderate to vigorous PA at 8 and 24 weeks. The findings from this study could transform care for IHD patients who are hopeless by promoting self-management of important PA goals that can contribute to better health outcomes.
Description: Mean minutes/day moderate to vigorous physical activity
Measure: ActiGraph GT9X Link Accelerometer Time: Month 12Description: Participant's report of current level of state hopelessness. Total score range= 1 (better) to 4 (worse).
Measure: State-Trait Hopelessness Scale Time: Month 12Description: Participant's report of exercise self-regulation level. Total score range= 1 (worse) to 7 (better).
Measure: Exercise Self-Regulation Questionnaire Time: Month 12Description: Participant's report of perceived social support level. Total score range= 1 (worse) to 30 (better).
Measure: ENRICHD Social Support Inventory Time: Month 12Description: Comorbidity score based on medical record abstraction. Total score range= 0 (better) to 100 (worse).
Measure: Charlson Comorbidity Index Time: Week 1Description: Participant's report of participation level with exercise in home, community or cardiac rehabilitation program
Measure: Cardiac Rehabilitation Exercise Participation Tool Time: Month 12Description: Participant's report of mean level of depressive symptoms. Total score range= 0 (better) to 27 (worse).
Measure: Patient Health Questionnaire-9 Time: Month 12Description: Participant's report of mean level of well-being. Total score range= 4 (better) to 20 (worse).
Measure: PROMIS-29 Time: Month 12Description: Participant's report of mean level state and trait hope. Total score range= 8 (worse) to 64 (better).
Measure: Snyder State Trait Scales Time: Month 12Description: Participant's report of mean level of quality of life. Total score range= 1 (better) to 5 (worse).
Measure: EuroQol (EQ-5d-5L) Time: Month 12Description: Participant's report of COVID-19 symptoms, diagnosis, testing, and social distancing. No score range (14 items).
Measure: Multi-Ethnic Study of Atherosclerosis (MESA) COVID-19 Questionnaire Time: Month 12Description: Participant's report of impact on routine; income/ employment; access to food, medical and mental health care, extended family; and stress. No range (12 items)
Measure: Coronavirus Impact Scale Time: Month 12Pre-market clinical evaluation of the everolimus eluting ESPRIT™ BTK System for the planned treatment of narrowed infrapopliteal lesions.
Description: It includes freedom from: above ankle amputation in index limb, 100% total occlusion of target vessel and clinically-driven target lesion revascularization (CD-TLR).
Measure: Composite of Limb Salvage and Primary Patency at 6 Months Time: At 6 monthsDescription: MALE includes above ankle amputation in index limb, major re-intervention at 6 months and POD includes perioperative (30 day) mortality.
Measure: Freedom from MALE+POD (Major Adverse Limb Event + Peri-Operative Death) Time: At 30 days (for POD) and 6 months (for MALE)Description: Successful target lesion treatment is defined as final diameter stenosis < 30% with final number of run-off vessels equivalent to or greater than number of run-off vessels at pre-procedure, with no residual dissection NHLBI grade ≥ type C, and no transient or sustained angiographic complications (e.g. distal embolization, perforation, thrombosis). Achieved using balloons plus ESPRIT BTK in the treatment arm and balloons in the control arm. This is defined on a per lesion basis.
Measure: Number of Participants with Acute Procedure Success Time: Immediately after the procedureDescription: Device success is defined on a per device basis, as the achievement of successful delivery and deployment of the study device(s) at the intended target lesion and successful withdrawal of the delivery catheter.
Measure: Number of Participants with Device Success Time: During the procedureDescription: Technical success is defined on a per lesion basis as the attainment of a final residual stenosis of < 30% at the intended target lesion(s) following use of the study device(s). Standard pre-dilatation catheters and post-dilatation catheters (if applicable) may be used. Bailout at lesion level does not impact technical success if the above criteria are met.
Measure: Number of Participants with Technical Success Time: During the procedureDescription: Clinical success is defined on a per patient basis, as the attainment of a final residual stenosis of < 30% using the study device(s) and/or any adjunctive device at all intended target lesion(s) without complications within 2 days after the index procedure or at hospital discharge, whichever is sooner.
Measure: Number of Participants with Clinical Success Time: Within 2 days after the index procedure or at hospital dischargeDescription: Acute gain is defined as the difference between post- and preprocedural minimal lumen diameter (MLD).
Measure: Number of Participants with Angiographic acute gain (in-segment) Time: Immediately after the procedureDescription: Acute gain is defined as the difference between post- and preprocedural minimal lumen diameter (MLD). Angiographic acute gain (in-device) will be assessed for ESPRIT arm only
Measure: Number of Participants with Angiographic acute gain (in-device) Time: Immediately after the procedureDescription: Composite of Limb Salvage and Primary Patency includes freedom from: above ankle amputation in index limb, 100% total occlusion of target vessel and clinically-driven target lesion revascularization (CD-TLR).
Measure: Composite of Limb Salvage and Primary Patency Time: At 1 month, 3 months, 6 months, 1 year and annually through 5 yearsDescription: MALE includes above ankle amputation in index limb, major re-interventions at 1 month, 3 months, 6 months, 1 year and annually through 5 years, and POD includes perioperative (30 day) mortality.
Measure: Freedom From MALE+POD (Major Adverse Limb Event + Peri-Operative Death) Time: At 1 month, 3 months, 6 months, 1 year and annually through 5 yearsDescription: Freedom from re-narrowing of the artery following the alleviation of a previous narrowing. It is defined as the presence of a hemodynamically significant restenosis (≥ 50%), as determined by angiography.
Measure: Freedom From Restenosis Time: At 1 month, 3 months, 6 months, 1 year and annually through 5 yearsDescription: All-cause Death composed of cardiac death, vascular death and non-cardiovascular death
Measure: Number of All-cause Death Time: At 1 month, 3 months, 6 months, 1 year and annually through 5 yearsDescription: Arterial thrombosis is defined as a total occlusion documented by duplex ultrasound and/or angiography at the site of the treated lesion with or without symptoms. Acute thrombosis: 0 - 24 hours post study procedure Subacute thrombosis: > 24 hours - 30 days post study procedure Late thrombosis: 31 days - 1 year post-procedure Very late thrombosis: > 1 year post-procedure Thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the arterial sheath has been removed and the subject has left the interventional lab.
Measure: Number of Participants with Arterial Thrombosis Time: At 1 month, 3 months, 6 months, 1 year and annually through 5 yearsDescription: Major Limb Re-interventions includes the creation of a new bypass graft, bypass graft revision, the use of thrombectomy or thrombolysis, or revascularization
Measure: Number of Participants with Major Re-intervention on index limb Time: At 1 month, 3 months, 6 months, 1 year and annually through 5 yearsDescription: Primary assisted patency is defined as patency of the target lesion following endovascular reintervention at the target vessel site in case of symptomatic restenosis
Measure: Primary Assisted Patency Time: At 1 month, 3 months, 6 months, 1 year and annually through 5 yearsDescription: Secondary patency is defined as patency of the target lesion after treatment of a (re)occlusion of the index lesion
Measure: Secondary Patency Time: At 1 month, 3 months, 6 months, 1 year and annually through 5 yearsDescription: CD-TLR is the repeat intervention on the target lesion due to recurrent symptoms AND stenosis > 70% by angiography
Measure: Number of Participants with Clinically-driven Target Lesion Revascularization (CD-TLR) Time: At 1 month, 3 months, 6 months, 1 year and annually through 5 yearsDescription: Wound assessment will be performed to determine whether the wound is improving (i.e. healing), not changing, or worsening.
Measure: Target Wound Assessment for Healing Time: At 14 days, 30 days, 42 days and 90 daysDescription: Wound Assessment for Infection will be performed to determine the clinical indication of the presence or absence of infection.
Measure: Target Wound Assessment for Infection Time: At 14 days, 30 days, 42 days and 90 daysDescription: The Rutherford Becker scale is a classification system for claudication and limb ischemia. Categories and Clinical Description: Category 0 = Asymptomatic, no hemodynamically significant occlusive disease Grade I (Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication) Grade II (Category 4 = Ischemic rest pain) Grade III (Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable).
Measure: Measurement of subject's Rutherford Becker Clinical Category, and change from baseline for the treated limb Time: At baseline,1 month, 3 months, 6 months, 1 year and annually through 5 yearsAbout 5% of COVID-19 patients may present symptoms related to acute ischemic stroke (AIS). Treatment-management and outcomes related to mechanical thrombectomy (MT) for COVID-19 infected patients harboring large vessel occlusion is largely unknown. This multicentric study aims to investigate morbidity, mortality and neurological outcomes after MT performed in patients with COVID-19 infection.
Description: Intrahospital mortality after MT for COVID-19 infected patients harboring large vessel occlusion
Measure: Intrahospital mortality Time: 1dayDescription: short-term morbidity after MT for COVID-19 infected patients harboring large vessel occlusion
Measure: short-term morbidity Time: 1 dayDescription: Angiographic success after MT for COVID-19 infected patients harboring large vessel occlusion
Measure: Angiographic success Time: 1 dayA multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of Temsirolimus Perivascular Injection 0.1 mg/mL on the incidence of ischemia-driven major amputation, clinically driven target lesion revascularization, and clinically relevant target lesion occlusion after revascularization of lesions below the knee in patients with symptomatic Rutherford 3-5 peripheral artery disease. The primary safety endpoint will be gathered at 1-month post-index procedure. The primary efficacy endpoint will be gathered at 6 months post-index procedure. Participants will be followed for up to 5 years post-index procedure.
Description: Superiority of treatment vs. control group in the composite freedom from the following: Clinically Relevant Target Lesion Occlusion Clinically Driven Target Lesion Revascularization Ischemia-Driven Major Amputation of the Target Limb
Measure: Freedom from Cinical Relevant Target Lesion Failure Time: 6 MonthsDescription: Noninferiority of treatment vs. control groups in the composite freedom from Major Adverse Limb Event (MALE) in the target limb or Perioperative Death (POD)
Measure: MALE + POD Time: 30 DaysDescription: Superiority of treatment vs. control group in the composite freedom from the following: Target Lesion Occlusion Clinically Driven Target Lesion Revascularization Ischemia-Driven Major Amputation of the target limb
Measure: Freedom from Target Lesion Failure Time: 6 MonthsDescription: Death at the following time points
Measure: To determine non-inferiority in long-term mortality rate Time: 12, 24, 36, 48, 60 monthsDescription: Composite of all-cause death or MALE of the target limb
Measure: To determine non-inferiority in freedom from all-cause death or major adverse limb event. Time: 30 days, 6, 12 monthsDescription: Freedom from death and ischemia-driven major amputation of the target limb
Measure: To determine non-inferiority in amputation-free survival. Time: 30 days, 6, 12, 24 monthsDescription: AEs/ARs will be categorized into one of the following: MALE of the target limb Non-MALE target limb SAE/SAR Other SAE/SAR Non-serious AE/AR AEs/ARs will further be classified as: Expected UADE SUSAR AEs/ARs will also be classified for relatedness (definitely, probably, possibly or not) to the following: Revascularization procedure Use of the Bullfrog device The study drug
Measure: Safety and tolerability will be assessed from overall rate of adverse events (subclassified as major, serious, non-serious, unanticipated, revascularization procedure-related, device-related and drug-related). Time: 30 days, 6, 12, 24 monthsDescription: Taken individually: Ischemia-driven major amputation of the target limb CD-TLR Clinically relevant target lesion occlusion Any target lesion occlusion
Measure: Change of the individual components of the primary and secondary endpoints (ischemia-driven major amputation, clinically driven target lesion revascularization, clinically relevant target lesion occlusion or all target lesion occlusion) Time: 6, 12, 24 monthsDescription: MALE of the target limb
Measure: Freedom from major adverse limb events Time: 30 days, 6, 12, 24 monthsDescription: Total size of foot wounds on the target limb, percent and absolute change from baseline Status of foot wounds on the target limb Unassisted wound healing
Measure: Composite of the following wound healing measures Time: 30 days, 6, 12 monthsDescription: Unplanned minor amputation rate, overall and by level (forefoot, midfoot, hindfoot)
Measure: Reduction in unplanned minor amputations Time: 30 days, 6, 12 monthsDescription: Rutherford category and change from baseline
Measure: Rutherford score improvement Time: 30 days, 6, 12, 24 monthsDescription: WIfI category and change from baseline
Measure: WIfI score improvement Time: 30 days, 6, 12, 24 monthsDescription: Ankle-brachial index and change from baseline Toe-brachial index and change from baseline Toe pressure and change from baseline
Measure: Composite of hemodynamic improvement measures (ABI, TBI and toe pressure) Time: 30 days, 6, 12, 24 monthsDescription: VascuQoL results and change from baseline
Measure: Patient reported quality of life benefits (VascuQoL) Time: 30 days, 6, 12, 24 monthsDescription: WIQ results and change from baseline
Measure: Patient reported outcomes (walking impairment questionnaire) benefits Time: 30 days, 6, 12, 24 monthsDescription: Primary patency rate Primary assisted patency rate
Measure: Primary and primary assisted patency rates Time: 30 days, 6, 12, 24 monthsDescription: Primary sustained clinical improvement rate Secondary sustained clinical improvement rate
Measure: Primary and secondary sustained clinical improvement rates Time: 30 days, 6, 12, 24 monthsThis is a retrospective analytical study conducted at Vascular and Endovascular surgery Department, Mansoura University Hospital, including all patients admitted at the two periods first six months of 2019 and 2020.To demonstrate the effect of COVID-19 pandemic on the practice of emergency vascular surgery and critical limb threatening ischemia interventions by comparison two periods first six months of 2019 and 2020.
Description: The ICU admission caused by Pneumonia proved radio-logically at both periods
Measure: The ICU admission with associated Pneumonia Time: 6 monthsDescription: percentage of different diagnoses at both periods
Measure: Impact of COVID-19 on the different presentation of vascular surgery at the emergency Time: 6 monthsDescription: Mortality percentages at both periods
Measure: Mortality rates Time: 6 monthsThe AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use with the aim of confirming safety and performance throughout their expected lifetime, ensuring the continued acceptability of identified risks, detecting emerging risks on the basis of factual evidence, ensuring the continued acceptability of the benefit-risk ratio, and identifying possible systematic misuse or off-label usage such that the intended use can be verified as appropriate.
Description: Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive XIENCE BTK and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, and TLR Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive XIENCE BTK and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, and TLR Time: 30 daysDescription: Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive XIENCE BTK and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, and TLR Time: 12 monthsDescription: Composite of all-cause death, amputation, TLR, target lesion occlusion will be assessed among the patients who receive Absolute Pro LongLength (LL), Supera 7.5 Outer Diameter (OD), Xpert Pro and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, TLR, target lesion occlusion Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of all-cause death, amputation, TLR, target lesion occlusion will be assessed among the patients who receive Absolute Pro LongLength (LL), Supera 7.5 Outer Diameter (OD), Xpert Pro and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, TLR, target lesion occlusion Time: 30 daysDescription: Composite of all-cause death, amputation, TLR, target lesion occlusion will be assessed among the patients who receive Absolute Pro LongLength (LL), Supera 7.5 Outer Diameter (OD), Xpert Pro and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, TLR, target lesion occlusion Time: 12 monthsDescription: Composite of potential complications including implant success, occlusion success, migration will be assessed among the patients who receive AVP or AVP II or AVP 4 and its competitors.
Measure: Number of participants with composite of potential complications (Implant success, occlusion success,migration) Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of occlusion success and migration will be assessed among the patients who receive AVP or AVP II or AVP 4 and its competitors.
Measure: Number of participants with composite of occlusion success and migration Time: 30 daysDescription: Composite of vessel dissection, perforation, and thromboembolism during procedure will be assessed among the patients who receive PressureWire X and its competitors.
Measure: Number of participants with composite of vessel dissection, perforation, and thromboembolism Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Signal drift (Signal drift between measurements (Pd/Pa** pressure drift >0.03; <0.97 or >1.03) will be assessed among the patients who receive PressureWire X and its competitors.
Measure: Number of participants with signal drift (Signal drift between measurements (Pd/Pa** pressure drift >0.03; <0.97 or >1.03) Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Loss of capture (average time of loss of capture across patients) will be assessed among the patients who receive Pacel FDPC and its competitors.
Measure: Loss of capture Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of potential complications (venous thrombosis, pulmonary emboli, arrhythmias, perforation) will be assessed among the patientswho receive Pacel BPC and its competitors.
Measure: Number of participants with composite of potential complications (venous thrombosis, pulmonary emboli, arrhythmias, perforation) Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of all-cause death, MI or target lesion revascularization(TLR) will be assessed among the patients who receive MULTI-LINK 8or MULTI-LINK 8 LL or MULTI-LINK 8 SV and its competitors.
Measure: Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR) Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of all-cause death, MI or target lesion revascularization(TLR) will be assessed among the patients who receive MULTI-LINK 8or MULTI-LINK 8 LL or MULTI-LINK 8 SV and its competitors.
Measure: Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR) Time: 30 daysDescription: Composite of all-cause death, MI or target lesion revascularization(TLR) will be assessed among the patients who receive MULTI-LINK 8or MULTI-LINK 8 LL or MULTI-LINK 8 SV and its competitors.
Measure: Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR) Time: 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports